These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22612853)

  • 1. Early detection of pharmacovigilance signals with automated methods based on false discovery rates: a comparative study.
    Ahmed I; Thiessard F; Miremont-Salamé G; Haramburu F; Kreft-Jais C; Bégaud B; Tubert-Bitter P
    Drug Saf; 2012 Jun; 35(6):495-506. PubMed ID: 22612853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area.
    Grundmark B; Holmberg L; Garmo H; Zethelius B
    Eur J Clin Pharmacol; 2014 May; 70(5):627-35. PubMed ID: 24599513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study.
    Ahmed I; Thiessard F; Miremont-Salamé G; Bégaud B; Tubert-Bitter P
    Clin Pharmacol Ther; 2010 Oct; 88(4):492-8. PubMed ID: 20811349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.
    Alvarez Y; Hidalgo A; Maignen F; Slattery J
    Drug Saf; 2010 Jun; 33(6):475-87. PubMed ID: 20486730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two drug safety signals in a pharmacovigilance data mining framework.
    Tubert-Bitter P; Bégaud B; Ahmed I
    Stat Methods Med Res; 2016 Apr; 25(2):615-29. PubMed ID: 23070598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of an automated signal detection method in the French pharmacovigilance database: a feasibility study.
    Pizzoglio V; Ahmed I; Auriche P; Tuber-Bitter P; Haramburu F; Kreft-Jaïs C; Miremont-Salamé G;
    Eur J Clin Pharmacol; 2012 May; 68(5):793-9. PubMed ID: 22143912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
    Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
    Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting.
    Ahmed I; Haramburu F; Fourrier-Réglat A; Thiessard F; Kreft-Jais C; Miremont-Salamé G; Bégaud B; Tubert-Bitter P
    Stat Med; 2009 Jun; 28(13):1774-92. PubMed ID: 19360795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
    Caster O; Aoki Y; Gattepaille LM; Grundmark B
    Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of three signal-detection algorithms using a highly inclusive reference event database.
    Hochberg AM; Hauben M; Pearson RK; O'Hara DJ; Reisinger SJ; Goldsmith DI; Gould AL; Madigan D
    Drug Saf; 2009; 32(6):509-25. PubMed ID: 19459718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. False discovery rate estimation for frequentist pharmacovigilance signal detection methods.
    Ahmed I; Dalmasso C; Haramburu F; Thiessard F; Broët P; Tubert-Bitter P
    Biometrics; 2010 Mar; 66(1):301-9. PubMed ID: 19432790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases.
    Avillach P; Salvo F; Thiessard F; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Bégaud B; Moore N; Pariente A;
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):186-94. PubMed ID: 23670805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class-imbalanced subsampling lasso algorithm for discovering adverse drug reactions.
    Ahmed I; Pariente A; Tubert-Bitter P
    Stat Methods Med Res; 2018 Mar; 27(3):785-797. PubMed ID: 27114328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer.
    Matsushita Y; Kuroda Y; Niwa S; Sonehara S; Hamada C; Yoshimura I
    Drug Saf; 2007; 30(8):715-26. PubMed ID: 17696584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of combining change-point analysis with disproportionality analysis in pharmacovigilance signal detection.
    Trinh NTH; Solé E; Benkebil M
    Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):370-376. PubMed ID: 29992679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance.
    Roux E; Thiessard F; Fourrier A; Bégaud B; Tubert-Bitter P
    IEEE Trans Inf Technol Biomed; 2005 Dec; 9(4):518-27. PubMed ID: 16379369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures.
    Ang PS; Chen Z; Chan CL; Tai BC
    Expert Opin Drug Saf; 2016 May; 15(5):583-90. PubMed ID: 26996192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance.
    Lee I; Lee TA; Crawford SY; Kilpatrick RD; Calip GS; Jokinen JD
    Expert Opin Drug Saf; 2020 Oct; 19(10):1357-1366. PubMed ID: 32662668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.